Not applicableStudy completedNCT01076868What this trial is testingIncidence of Vivax Along the Thai Burma BorderWho this might be right forVivax Malaria University of Oxford 403
Testing effectiveness (Phase 2)WithdrawnNCT00577668What this trial is testingA Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD)Who this might be right forMultiple Myeloma University of Arkansas
Testing effectiveness (Phase 2)Enrolling By InvitationNCT06931613What this trial is testingAutologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab TreatmentWho this might be right forRelapsed or Refractory Hodgkin LymphomaChildrenNivolumab+1 more St. Petersburg State Pavlov Medical University 20
Testing effectiveness (Phase 2)UnknownNCT04353479What this trial is testingCombined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid LeukemiaWho this might be right forAcute Myeloid Leukemia Shanghai Jiao Tong University School of Medicine 29
Testing effectiveness (Phase 2)Study completedNCT00373646What this trial is testingThalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma PatientsWho this might be right forMALT Lymphoma Medical University of Vienna 8
Testing effectiveness (Phase 2)Study completedNCT02614326What this trial is testingMemFlex to Prevent Depressive RelapseWho this might be right forMajor Depressive Disorder Medical Research Council Cognition and Brain Sciences Unit 70
Testing effectiveness (Phase 2)Looking for participantsNCT06138990What this trial is testingPharmacoscopy-guided Clinical Standard-of-care in r/r AMLWho this might be right forAML, Adult ETH Zurich 88
Testing effectiveness (Phase 2)Study completedNCT00156013What this trial is testingClofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)Who this might be right forLymphoma, B-CellLymphoma, Non-Hodgkin Oncology Specialists, S.C. 33
Testing effectiveness (Phase 2)Active Not RecruitingNCT03075696What this trial is testingA Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's LymphomaWho this might be right forNon-Hodgkin's Lymphoma Hoffmann-La Roche 940
Testing effectiveness (Phase 2)Study completedNCT01883362What this trial is testingStandard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AMLWho this might be right forAcute Myeloid Leukemia Novartis Pharmaceuticals 60
Early research (Phase 1)UnknownNCT06316076What this trial is testingSafety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune DiseasesWho this might be right forSystemic Lupus ErythematosusAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisIdiopathic Inflammatory Myopathies+1 more RenJi Hospital 48
Not applicableLooking for participantsNCT07356882What this trial is testingEuropean Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin LymphomaWho this might be right forClassical Hodgkin Lymphoma Assistance Publique - Hôpitaux de Paris 400
Testing effectiveness (Phase 2)Ended earlyNCT00754923What this trial is testingSorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung CancerWho this might be right forLung Cancer Ohio State University Comprehensive Cancer Center 11
Early research (Phase 1)Looking for participantsNCT06737523What this trial is testingChiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AMLWho this might be right forAcute Myeloid LeukemiaRelapseRefractory AML The First Affiliated Hospital of Xiamen University 30
Very early researchWithdrawnNCT06866080What this trial is testingLCAR-AIO in Subjects With Relapsed/Refractory Autoimmune DiseasesWho this might be right forRelapsed/Refractory Autoimmune Diseases Nanjing Legend Biotech Co.
Very early researchUnknownNCT03795779What this trial is testingCLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic MalignanciesWho this might be right forHematologic MalignancyAcute Myeloid LeukemiaMyelodysplastic Syndromes+2 more iCell Gene Therapeutics 20
Large-scale testing (Phase 3)Ended earlyNCT00256776What this trial is testingMMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous TransplantationWho this might be right forMultiple Myeloma European Society for Blood and Marrow Transplantation 269
Large-scale testing (Phase 3)Study completedNCT03952091What this trial is testingTJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaWho this might be right forMultiple Myeloma in RelapseRefractory Multiple Myeloma TJ Biopharma Co., Ltd. 289
Testing effectiveness (Phase 2)Study completedNCT00006013What this trial is testingSU5416 in Treating Patients With Refractory or Relapsed Multiple MyelomaWho this might be right forMultiple Myeloma and Plasma Cell Neoplasm Fox Chase Cancer Center 21
Testing effectiveness (Phase 2)Study completedNCT02340780What this trial is testingBuparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic LeukemiaWho this might be right forChronic Lymphocytic Leukemia Canadian Cancer Trials Group 14